C. Schlichting

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +10

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Endothelial Determinants of Dendritic Cell Adhesion and Migration

Michael Weis, C. Schlichting, Edgar G. Engleman et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2002 · 103 citations · Full text

Life Sciences, Cell Biology, Immunology +17

295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

Axel Grothey, Kim Jordan, O Kellner et al. · European Journal of Cancer Supplements · 2003 · 63 citations

Medicine, Oncology, Pharmacology +14

Capecitabine/ irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study

Axel Grothey, Kim Jordan, O Kellner et al. · Journal of Clinical Oncology · 2004 · 40 citations

Medicine, Oncology, Pharmacotherapy +14